Clinical Trial Update: An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) [Phase 3]

View source ↗

Summary

The Phase 3 extended access program for bardoxolone methyl in chronic kidney disease was terminated, with results posted in March 2024. The trial included patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome
• Autosomal Dominant Polycystic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• Bardoxolone Methyl (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Chronic Kidney Diseases, Alport Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2024-03-19